Drug intelligence / Profile preview

MAN-11

Development stage: Preclinical
Lead developer: Mannin Research

Overview

MAN-11 is a biologic drug candidate developed by Mannin Research in co-development with Q BioMed. It is part of Mannin's Tie2 platform, which focuses on therapies for various vascular diseases. MAN-11 is specifically being developed for the treatment of glaucoma. The drug likely acts as a Tie2 agonist, aiming to promote vascular stability, reduce vascular leakage, and improve endothelial cell survival.

Targets

TEK (Tie2)

Beyond the preview

Go deeper on MAN-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAN-11.

Explore the full profile